Disease Detail

ID DOID:9538
Name multiple myeloma
Definition A myeloid neoplasm that is located in the plasma cells in bone marrow.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm multiple myeloma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown ABT-348 multiple myeloma not applicable detail...
IKZF1 wild-type Lenalidomide multiple myeloma sensitive detail...
FGFR3 over exp MFGR1877S multiple myeloma sensitive detail...
FGFR3 Y373C FGFR3 over exp AZ8010 multiple myeloma sensitive detail...
FGFR3 K650E FGFR3 over exp HRAS K117E PD173074 multiple myeloma sensitive detail...
FGFR3 Y373C FGFR3 over exp PD173074 multiple myeloma sensitive detail...
FGFR3 G384D FGFR3 over exp PD173074 multiple myeloma decreased response detail...
FGFR3 G384D FGFR3 over exp AZD4547 multiple myeloma decreased response detail...
FGFR3 G384D FGFR3 over exp AZ8010 multiple myeloma decreased response detail...
Unknown unknown BAY 1238097 multiple myeloma not applicable detail...
Unknown unknown Bortezomib + Dexamethasone + Panobinostat multiple myeloma not applicable detail...
Unknown unknown Carfilzomib + Ricolinostat multiple myeloma not applicable detail...
Unknown unknown Citarinostat + Pomalidomide multiple myeloma not applicable detail...
Unknown unknown KW-2478 multiple myeloma not applicable detail...
Unknown unknown Torkinib multiple myeloma not applicable detail...
Unknown unknown Bortezomib + Torkinib multiple myeloma not applicable detail...
Unknown unknown Selumetinib multiple myeloma no benefit detail...
NRAS mutant Trametinib multiple myeloma sensitive detail...
BRAF mutant Trametinib multiple myeloma sensitive detail...
Unknown unknown Dexamethasone + Pegylated liposomal-doxorubicin + Selinexor multiple myeloma not applicable detail...
Unknown unknown GSK1904529A multiple myeloma not applicable detail...
Unknown unknown Marizomib multiple myeloma not applicable detail...
Unknown unknown NSC126405 multiple myeloma not applicable detail...
Unknown unknown Daratumumab + Dexamethasone + Lenalidomide multiple myeloma not applicable detail...
Unknown unknown Dexamethasone + Lenalidomide + Ricolinostat multiple myeloma not applicable detail...
Unknown unknown AZD5153 multiple myeloma not applicable detail...
FGFR3 Y373C E7090 multiple myeloma sensitive detail...
Unknown unknown ONC201 multiple myeloma not applicable detail...
Unknown unknown Dinaciclib multiple myeloma not applicable detail...
Unknown unknown Dinaciclib + Veliparib multiple myeloma not applicable detail...
Unknown unknown B02 + Veliparib multiple myeloma not applicable detail...
Unknown unknown Dinaciclib + Doxorubicin multiple myeloma not applicable detail...
Unknown unknown Bortezomib + Tapalumab multiple myeloma not applicable detail...
Unknown unknown Daratumumab multiple myeloma not applicable detail...
Unknown unknown Bortezomib + Daratumumab + Dexamethasone multiple myeloma not applicable detail...
Unknown unknown Bortezomib + Dexamethasone + Ricolinostat multiple myeloma not applicable detail...
Unknown unknown Ricolinostat multiple myeloma no benefit detail...
Unknown unknown bb2121 multiple myeloma not applicable detail...
Unknown unknown Dexamethasone + Elotuzumab + Lenalidomide multiple myeloma not applicable detail...
MET positive Ficlatuzumab multiple myeloma predicted - sensitive detail...
Unknown unknown MS417 multiple myeloma not applicable detail...
Unknown unknown ABBV-075 multiple myeloma not applicable detail...
Unknown unknown Tivantinib multiple myeloma no benefit detail...
Unknown unknown KDM5-C70 multiple myeloma not applicable detail...
Unknown unknown Cyclophosphamide + LCL161 multiple myeloma not applicable detail...
Unknown unknown Lenalidomide multiple myeloma not applicable detail...
Unknown unknown Cyclophosphamide + Dexamethasone + Lenalidomide multiple myeloma not applicable detail...
Unknown unknown TAS4464 multiple myeloma not applicable detail...
Unknown unknown Carfilzomib + TG02 multiple myeloma not applicable detail...
Unknown unknown ABBV-075 + Bortezomib multiple myeloma not applicable detail...
Unknown unknown ABBV-075 + Azacitidine multiple myeloma not applicable detail...
Unknown unknown Bortezomib + DT204 multiple myeloma not applicable detail...
Unknown unknown Carfilzomib + DT204 multiple myeloma not applicable detail...
Unknown unknown DT204 + Ixazomib multiple myeloma not applicable detail...
Unknown unknown Bendamustine + Veliparib multiple myeloma not applicable detail...
Unknown unknown SJB3-019A multiple myeloma not applicable detail...
Unknown unknown Bortezomib + SJB3-019A multiple myeloma not applicable detail...
Unknown unknown Ricolinostat + SJB3-019A multiple myeloma not applicable detail...
Unknown unknown Lenalidomide + SJB3-019A multiple myeloma not applicable detail...
Unknown unknown Pomalidomide + SJB3-019A multiple myeloma not applicable detail...
Unknown unknown Bortezomib + Tinostamustine multiple myeloma not applicable detail...
Unknown unknown Carfilzomib + Tinostamustine multiple myeloma not applicable detail...
Unknown unknown Tinostamustine multiple myeloma not applicable detail...
Unknown unknown Delanzomib + Tinostamustine multiple myeloma not applicable detail...
Unknown unknown BC2059 multiple myeloma not applicable detail...
Unknown unknown BC2059 + Bortezomib multiple myeloma not applicable detail...
Unknown unknown Cabozantinib multiple myeloma no benefit detail...
Unknown unknown Isatuximab multiple myeloma not applicable detail...
Unknown unknown A-485 multiple myeloma not applicable detail...
Unknown unknown GNE-272 multiple myeloma not applicable detail...
Unknown unknown Filanesib multiple myeloma not applicable detail...
Unknown unknown Dexamethasone + Filanesib multiple myeloma not applicable detail...
Unknown unknown FT671 multiple myeloma not applicable detail...
Unknown unknown AMG 176 multiple myeloma not applicable detail...
Unknown unknown SNS-510 multiple myeloma not applicable detail...
KDM6A loss GSK343 multiple myeloma sensitive detail...
KDM6A loss GSK126 multiple myeloma sensitive detail...
Unknown unknown MV-NIS multiple myeloma not applicable detail...
Unknown unknown Dexamethasone + Marizomib + Pomalidomide multiple myeloma not applicable detail...
Unknown unknown Bevacizumab + Dexamethasone + Evofosfamide multiple myeloma not applicable detail...
Unknown unknown Dexamethasone + Evofosfamide multiple myeloma not applicable detail...
Unknown unknown CB-5083 multiple myeloma sensitive detail...
Unknown unknown GSK2857916 multiple myeloma not applicable detail...
Unknown unknown DFRF4539A multiple myeloma no benefit detail...
Unknown unknown Bortezomib + Daratumumab + Melphalan + Prednisone multiple myeloma not applicable detail...
Unknown unknown Daratumumab + Dexamethasone + Pomalidomide multiple myeloma not applicable detail...
Unknown unknown Dexamethasone + Selinexor multiple myeloma not applicable detail...
Unknown unknown Bortezomib multiple myeloma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed
NCT00734877 Phase III Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide Bortezomib + Dexamethasone + Melphalan + Thalidomide UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma Recruiting
NCT00903968 Phase Ib/II Bortezomib + Plerixafor Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma Completed
NCT00918333 Phase Ib/II Everolimus + Panobinostat Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Active, not recruiting
NCT01084252 Phase Ib/II Isatuximab Dexamethasone + Isatuximab Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Active, not recruiting
NCT01146834 Phase III Bortezomib + Filgrastim Bortezomib + Cyclophosphamide + Filgrastim Bortezomib + Cyclophosphamide Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma Completed
NCT01163357 Phase I Sirolimus Bortezomib + Fludarabine + Melphalan Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma Active, not recruiting
NCT01177397 Phase Ib/II CC-223 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed
NCT01177683 Phase Ib/II Bendamustine + Bortezomib + Pegylated liposomal-doxorubicin Filgrastim Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma Terminated
NCT01208662 Phase III Bortezomib + Dexamethasone + Lenalidomide Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106) Active, not recruiting
NCT01239368 Phase I Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma Terminated
NCT01241708 Phase III Bortezomib Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma ((Mel/MelVel)) Recruiting
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed
NCT01287546 Phase I Emibetuzumab + Erlotinib Emibetuzumab + Trametinib Emibetuzumab A Study of LY2875358 in Participants With Advanced Cancer Completed
NCT01301807 Phase I Carfilzomib + Panobinostat Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM) Active, not recruiting
NCT01313897 Phase II Bortezomib UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (NK2010-35) Completed
NCT01323751 Phase Ib/II Bortezomib + Dexamethasone Ricolinostat Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Completed
NCT01326702 Phase Ib/II Veliparib Rituximab Bendamustine Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed
NCT01345019 Phase III Denosumab Zoledronic acid Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma Completed
NCT01353625 Phase I CC-115 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Active, not recruiting
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Active, not recruiting
NCT01428492 Phase I Afuresertib Bortezomib Dexamethasone Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma Completed
NCT01440582 Phase I Bortezomib + Dexamethasone + Lenalidomide + Panobinostat Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients Completed
NCT01453088 Phase II Melphalan Bortezomib Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older Recruiting
NCT01453101 Phase II Fludarabine + Melphalan Bortezomib Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Active, not recruiting
NCT01456689 Phase I Midazolam LGH447 A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma Completed
NCT01470131 Phase III Masitinib Bortezomib + Dexamethasone A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma Terminated
NCT01522872 Phase Ib/II Evofosfamide Bortezomib Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma Unknown status
NCT01524978 Phase II Vemurafenib Cetuximab A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers Completed
NCT01526096 Phase I Basiliximab Filgrastim Plerixafor Melphalan Stem Cell Transplantation for Patients With Multiple Myeloma Active, not recruiting
NCT01547806 Phase II Filgrastim Plerixafor Collection of Transplant Stem Cells for Plasma Cell Myeloma Completed
NCT01582295 Phase I Cabozantinib XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease Completed
NCT01587703 Phase I GSK525762 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Active, not recruiting
NCT01592370 Phase I Nivolumab Ipilimumab Lirilumab Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma Recruiting
NCT01609816 Phase Ib/II Dasatinib Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant Active, not recruiting
NCT01668719 Phase Ib/II Elotuzumab Bortezomib + Dexamethasone + Lenalidomide S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma Active, not recruiting
NCT01672736 Phase Ib/II Bortezomib + Dexamethasone + Linsitinib A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma Terminated
NCT01689987 Phase I Cyclophosphamide + Dexamethasone + Hydroxychloroquine + Sirolimus Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed
NCT01695330 Phase II Bortezomib Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens Terminated
NCT01711528 Phase I Bortezomib + Dexamethasone + Dinaciclib Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Completed
NCT01723020 Phase I AMG 232 A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma Completed
NCT01729091 Phase Ib/II Dexamethasone Elotuzumab Filgrastim Melphalan Lenalidomide Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma Active, not recruiting
NCT01729338 Phase II Bortezomib + Cyclophosphamide + Lenalidomide Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma Terminated
NCT01734928 Phase III Pomalidomide Bortezomib + Dexamethasone Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Active, not recruiting
NCT01794507 Phase I Bortezomib + Dexamethasone + Venetoclax A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Suspended
NCT01794520 Phase I Venetoclax Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma Suspended
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Active, not recruiting
NCT01827137 Phase I WT1 vaccine Lenalidomide Sargramostim WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation Unknown status
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated
NCT01849783 Phase II Bortezomib + Dexamethasone + Melphalan + Thalidomide Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma Active, not recruiting
NCT01863550 Phase III Dexamethasone Lenalidomide Carfilzomib Bortezomib Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Recruiting
NCT01866293 Phase Ib/II Cabozantinib Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma Completed
NCT01889420 Phase I Dexamethasone + Everolimus + Pomalidomide Phase I Trial of Everolimus, Pomalidomide and Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma Terminated
NCT01919086 Phase II Lenalidomide Bortezomib + Dexamethasone Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma Active, not recruiting
NCT01947140 Phase Ib/II Pralatrexate + Romidepsin Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (PDX+Romi) Recruiting
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Active, not recruiting
NCT01954784 Phase I Bortezomib + Cyclosporine + Mycophenolate mofetil Lenalidomide Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma Terminated
NCT01955434 Phase II Cyclophosphamide + LCL161 SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed
NCT01962792 Phase Ib/II Carfilzomib + Ibrutinib Dexamethasone Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma Completed
NCT01965353 Phase I Bortezomib + Dexamethasone + Lenalidomide + Panobinostat A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma Active, not recruiting
NCT01989598 Phase II Trametinib + Uprosertib Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma Active, not recruiting
NCT01995708 Phase I CT7/MAGE-A3/WT1 mRNA-electroporated LCs CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Active, not recruiting
NCT01997840 Phase Ib/II Dexamethasone + Pomalidomide + Ricolinostat ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Active, not recruiting
NCT01998971 Phase I Pomalidomide Bortezomib + Dexamethasone Melphalan Thalidomide Lenalidomide Prednisone Daratumumab Carfilzomib Diphenhydramine Montelukast A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma Active, not recruiting
NCT02030483 Phase I Palbociclib Dexamethasone Lenalidomide Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma Terminated
NCT02034110 Phase II Dabrafenib + Trametinib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting
NCT02036502 Phase I Dexamethasone Lenalidomide + Pembrolizumab A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) Active, not recruiting
NCT02057640 Phase Ib/II Dexamethasone + Ixazomib + Panobinostat MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma Active, not recruiting
NCT02061761 Phase Ib/II Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Recruiting
NCT02077959 Phase Ib/II Lenalidomide + Pidilizumab Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed
NCT02086552 Phase II Lenalidomide + Sonidegib Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma Active, not recruiting
NCT02098109 Phase II Plerixafor Filgrastim Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Completed
NCT02099539 Phase Ib/II ALT-803 A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma Active, not recruiting
NCT02101944 Phase I Carfilzomib + Dexamethasone + Reolysin Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma Recruiting
NCT02104427 Phase II TG-0054 Filgrastim PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients Completed
NCT02110563 Phase I DCR-MYC Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Terminated
NCT02136134 Phase III Daratumumab Bortezomib + Dexamethasone Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting
NCT02140840 Phase II Trametinib A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib Withdrawn
NCT02144038 Phase Ib/II Alpelisib + LGH447 LGH447 Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma Completed
NCT02157636 Phase I CPI-0610 A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma Completed
NCT02159365 Phase II Dexamethasone + Elotuzumab + Lenalidomide Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Completed
NCT02186834 Phase Ib/II Dexamethasone + Pegylated liposomal-doxorubicin + Selinexor Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma Active, not recruiting
NCT02188368 Phase II Bortezomib + Carfilzomib + Clarithromycin Pegylated liposomal-doxorubicin + Pomalidomide Pomalidomide Pomalidomide for Lenalidomide for Failures Recruiting
NCT02189343 Phase I Dexamethasone + Pomalidomide + Ricolinostat Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed-and-Refractory Multiple Myeloma Active, not recruiting
NCT02192775 Phase II MV-NIS UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus Recruiting
NCT02195479 Phase III Bortezomib Daratumumab Melphalan A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma Active, not recruiting
NCT02199665 Phase I Carfilzomib + Dexamethasone + Selinexor Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Recruiting
NCT02204553 Phase I Bortezomib + Dexamethasone + Panobinostat Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma No longer available
NCT02211014 Phase I Acalabrutinib Dexamethasone An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma Completed
NCT02220608 Phase I Bortezomib + Filgrastim Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Completed
NCT02223598 Phase I CB-5083 CB-5083 + Dexamethasone A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102) Terminated
NCT02235740 Phase I Carfilzomib Afuresertib + Carfilzomib A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) Terminated
NCT02252263 Phase I Urelumab Lirilumab Elotuzumab A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma Completed
NCT02254551 Phase II Bortezomib + Sonidegib Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Terminated
NCT02283775 Phase I Dexamethasone + Isatuximab + Pomalidomide SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR) Active, not recruiting
NCT02289222 Phase Ib/II Dexamethasone + Pembrolizumab + Pomalidomide Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma Terminated
NCT02308280 Phase II Bortezomib Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients Active, not recruiting
NCT02328014 Phase Ib/II ACP-319 Acalabrutinib ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies Active, not recruiting
NCT02331368 Phase II Lenalidomide Melphalan Pembrolizumab Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma Completed
NCT02332850 Phase I Carfilzomib + Isatuximab SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma Recruiting
NCT02336815 Phase II Dexamethasone + Selinexor Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies Active, not recruiting
NCT02343042 Phase Ib/II Bortezomib Dexamethasone + Selinexor Pomalidomide Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma Recruiting
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Recruiting
NCT02367196 Phase I CC-90002 + Rituximab CC-90002 A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers Recruiting
NCT02368301 Phase I Dexamethasone + Elotuzumab + Lenalidomide Expanded Access Treatment Protocol CA204-143 Approved for marketing
NCT02372240 Phase Ib/II Dexamethasone + VLX1570 A Study of VLX1570 and Dexamethasone in Myeloma Patients Terminated
NCT02375555 Phase II Elotuzumab Bortezomib + Dexamethasone + Lenalidomide Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM Active, not recruiting
NCT02391480 Phase I ABBV-075 A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Active, not recruiting
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib INCMGA00012 + Pemigatinib Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting
NCT02400242 Phase I Citarinostat Dexamethasone Pomalidomide Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma Active, not recruiting
NCT02401295 Phase I Celecoxib + Itraconazole + Tretinoin ATRA, Celecoxib, and Itraconazole as Maintenance Completed
NCT02426723 Phase I CWP232291 Dexamethasone + Lenalidomide Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients Completed
NCT02431208 Phase I Lenalidomide Atezolizumab A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM) Active, not recruiting
NCT02440464 Phase II Methotrexate + Tacrolimus Ixazomib Fludarabine + Melphalan Bortezomib Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) Active, not recruiting
NCT02441686 Phase II Bortezomib + Dexamethasone + Lenalidomide Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma Active, not recruiting
NCT02465060 Phase II Erdafitinib Copanlisib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Pertuzumab + Trastuzumab Dabrafenib + Trametinib Binimetinib Adavosertib Osimertinib Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Larotrectinib Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting
NCT02477878 Phase I BPX-601 Rimiducid Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Active, not recruiting
NCT02504359 Phase I Ixazomib Carmustine + Cytarabine + Etoposide + Melphalan Methotrexate + Tacrolimus Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Active, not recruiting
NCT02514382 Phase I Bortezomib + Dexamethasone + Reolysin Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Active, not recruiting
NCT02514668 Phase I Isatuximab A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma Active, not recruiting
NCT02548962 Phase Ib/II Ibrutinib Dexamethasone + Pomalidomide Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma Terminated
NCT02568943 Phase I Bortezomib + Dexamethasone + Panobinostat An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma Available
NCT02569320 Phase I AR-42 + Dexamethasone + Pomalidomide HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma Suspended
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Active, not recruiting
NCT02576977 Phase III Pomalidomide Pembrolizumab Dexamethasone Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) Active, not recruiting
NCT02579824 Phase I DS-3032b DS-3032b for Relapsed and/or Refractory (RR) Myeloma Active, not recruiting
NCT02579863 Phase III Pembrolizumab Dexamethasone Lenalidomide Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) Active, not recruiting
NCT02603887 Phase I Pembrolizumab Pembrolizumab for Smoldering Multiple Myeloma (SMM) Active, not recruiting
NCT02605356 Phase Ib/II Radium Ra 223 dichloride Bortezomib Dexamethasone Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma Withdrawn
NCT02612779 Phase II Dexamethasone + Elotuzumab + Pomalidomide A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide Active, not recruiting
NCT02616640 Phase I Pomalidomide Dexamethasone Durvalumab A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Active, not recruiting
NCT02628704 Phase II Carfilzomib + Dexamethasone + Selinexor Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma Withdrawn
NCT02633059 Phase Ib/II Dexamethasone + Idasanutlin + Ixazomib Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Recruiting
NCT02649790 Phase Ib/II KPT-8602 Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma Recruiting
NCT02654132 Phase II Dexamethasone + Pomalidomide Elotuzumab Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma Active, not recruiting
NCT02654990 Phase II Bortezomib + Dexamethasone + Panobinostat Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma Active, not recruiting
NCT02655458 Phase I Elotuzumab + Lenalidomide Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma Completed
NCT02658396 Phase I Bortezomib + GO-203-2C GO-203-2C + Bortezomib For Relapsed Or Refractory MM Withdrawn
NCT02658929 Phase I bb2121 Study of bb2121 in Multiple Myeloma Active, not recruiting
NCT02666209 Phase I Bortezomib + Dexamethasone + Ulocuplumab Dexamethasone + Lenalidomide + Ulocuplumab Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma No longer available
NCT02675452 Phase I AMG 176 AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
NCT02681302 Phase Ib/II Ipilimumab + Nivolumab Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001) Recruiting
NCT02684617 Phase I Dinaciclib + Pembrolizumab Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) Active, not recruiting
NCT02685826 Phase I Dexamethasone Durvalumab + Lenalidomide A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma Active, not recruiting
NCT02693535 Phase II Cobimetinib + Vemurafenib Regorafenib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Ipilimumab + Nivolumab Crizotinib Palbociclib Sunitinib Olaparib Cetuximab TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT02700841 Phase II Melphalan + PVX-410 Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation Suspended
NCT02703779 Phase II Bortezomib Filgrastim + Plerixafor Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) Recruiting
NCT02716805 Phase I Durvalumab + Tremelimumab Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant Terminated
NCT02718833 Phase II Bortezomib + Dexamethasone + Elotuzumab + Panobinostat A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma Active, not recruiting
NCT02719613 Phase II Bortezomib + Dexamethasone + Elotuzumab + Lenalidomide Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab Active, not recruiting
NCT02720510 Phase II Panobinostat Bortezomib + Dexamethasone + Lenalidomide A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) Terminated
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep Recruiting
NCT02722941 Phase II Panobinostat Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) Active, not recruiting
NCT02726581 Phase III Elotuzumab Nivolumab Dexamethasone + Pomalidomide Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma Active, not recruiting
NCT02755597 Phase III Bortezomib + Dexamethasone Bortezomib + Dexamethasone + Venetoclax A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Suspended
NCT02757326 Phase Ib/II ABC294640 ABC294640 in Refractory / Relapsed Multiple Myeloma Terminated
NCT02765854 Phase II Dexamethasone + Ixazomib + Lenalidomide Dexamethasone + Ixazomib Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement Recruiting
NCT02773030 Phase Ib/II Iberdomide Dexamethasone + Iberdomide Daratumumab + Dexamethasone + Iberdomide Bortezomib + Dexamethasone + Iberdomide A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM) Recruiting
NCT02780609 Phase Ib/II Dexamethasone + Melphalan + Selinexor Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Recruiting
NCT02784483 Phase I Atezolizumab Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma Suspended
NCT02786485 Phase I Rimiducid BPX-501 Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Withdrawn
NCT02802163 Phase Ib/II Carfilzomib + Dexamethasone + Lenalidomide + Panobinostat Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat Withdrawn
NCT02807454 Phase Ib/II Daratumumab + Dexamethasone + Durvalumab + Pomalidomide Daratumumab + Durvalumab A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003) Active, not recruiting
NCT02831686 Phase I Dexamethasone + Ixazomib + Selinexor A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma Active, not recruiting
NCT02833610 Phase II Denosumab A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency Recruiting
NCT02863991 Phase II ONC201 Oral ONC201 in Relapsed/Refractory Multiple Myeloma Recruiting
NCT02874742 Phase II Daratumumab Bortezomib + Dexamethasone + Lenalidomide Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Active, not recruiting
NCT02880228 Phase II Dexamethasone + Lenalidomide + Pembrolizumab Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant Completed
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Recruiting
NCT02899052 Phase II Carfilzomib + Dexamethasone + Venetoclax Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM) Suspended
NCT02906332 Phase II Pembrolizumab Dexamethasone Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) Active, not recruiting
NCT02928029 Phase Ib/II Bortezomib + Dexamethasone + Radium Ra 223 dichloride Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma Completed
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Recruiting
NCT02943473 Phase II Ibrutinib Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients Recruiting
NCT02948283 Phase 0 Metformin + Ritonavir Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Active, not recruiting
NCT02951819 Phase II Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma Active, not recruiting
NCT02952573 Phase II Dexamethasone + Erdafitinib Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement Recruiting
NCT02963493 Phase II Dexamethasone + Melflufen A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients (HORIZON) Recruiting
NCT02978235 Phase Ib/II TAS4464 A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma Terminated
NCT02990338 Phase III Dexamethasone + Isatuximab + Pomalidomide Dexamethasone + Pomalidomide Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM) Active, not recruiting
NCT02992483 Phase I MIK665 Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma Recruiting
NCT02998047 Phase I Lintuzumab-Ac225 A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma Recruiting
NCT03000452 Phase II Daratumumab + Durvalumab A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005) Completed
NCT03004287 Phase II Melphalan Carfilzomib Cisplatin Cyclophosphamide Lenalidomide Dexamethasone Daratumumab Bortezomib Etoposide Doxorubicin Thalidomide 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy Recruiting
NCT03015792 Phase Ib/II Dexamethasone + Ibrutinib + Lenalidomide Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant Suspended
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Recruiting
NCT03018405 Phase I NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Recruiting
NCT03030261 Phase II Melphalan Dexamethasone + Elotuzumab + Pomalidomide Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma Recruiting
NCT03031730 Phase I AMG 232 + Carfilzomib + Dexamethasone + Lenalidomide MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Recruiting
NCT03068351 Phase I TEN-010 Daratumumab + TEN-010 Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma Active, not recruiting
NCT03091257 Phase I Dabrafenib + Trametinib Dabrafenib Trametinib A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma Recruiting
NCT03104270 Phase II Carfilzomib + Dexamethasone + Elotuzumab + Pomalidomide Combination Study for High Risk Multiple Myeloma Patients Recruiting
NCT03106428 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies Recruiting
NCT03110562 Phase III Bortezomib + Dexamethasone + Selinexor Bortezomib + Dexamethasone Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON) Active, not recruiting
NCT03110822 Phase I Lenalidomide + Methylprednisolone + Ruxolitinib A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients Recruiting
NCT03111992 Phase I LCL161 + Spartalizumab CJM112 + Spartalizumab Spartalizumab Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma Recruiting
NCT03143985 Phase I Pomalidomide + TEW 7197 TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma Recruiting
NCT03145181 Phase I JNJ-64007957 Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma Recruiting
NCT03151811 Phase III Dexamethasone + Pomalidomide Dexamethasone + Melflufen A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN) Recruiting
NCT03168100 Phase II Bortezomib + Dexamethasone + Lenalidomide Dexamethasone + Elotuzumab + Lenalidomide 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma Withdrawn
NCT03168438 Phase I NY-ESO-1-c259T NY-ESO-1-c259T + Pembrolizumab NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma Recruiting
NCT03194867 Phase Ib/II Cemiplimab + Isatuximab Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Active, not recruiting
NCT03201250 Phase Ib/II Cabozantinib + Carfilzomib + Dexamethasone Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma Recruiting
NCT03218683 Phase I AZD5991 Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. Recruiting
NCT03221634 Phase II Daratumumab + Pembrolizumab Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) Withdrawn
NCT03227432 Phase II Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide Elotuzumab + Nivolumab An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma Withdrawn
NCT03246529 Phase III Filgrastim BKT140 + Filgrastim A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS) Recruiting
NCT03256045 Phase II Carfilzomib + Dexamethasone + Panobinostat Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Recruiting
NCT03266692 Phase I ACTR087 + SEA-BCMA Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma Recruiting
NCT03267888 Phase I Pembrolizumab Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma Recruiting
NCT03275285 Phase III Carfilzomib + Dexamethasone + Isatuximab Carfilzomib + Dexamethasone Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA) Active, not recruiting
NCT03288493 Phase I P-BCMA-101 CAR-T cells P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) Recruiting
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting
NCT03314181 Phase II Bortezomib + Daratumumab + Dexamethasone + Venetoclax Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Venetoclax A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma Suspended
NCT03315026 Phase II siltuximab Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis Recruiting
NCT03319667 Phase III Bortezomib + Dexamethasone + Lenalidomide Dexamethasone + Isatuximab + Lenalidomide Bortezomib + Dexamethasone + Isatuximab + Lenalidomide Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ) Active, not recruiting
NCT03333746 Phase II Lenalidomide + Nivolumab Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Terminated
NCT03357952 Phase I Daratumumab + JNJ-63723283 A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting
NCT03361306 Phase II Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple M Recruiting
NCT03361748 Phase II bb2121 Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) (bb2121) Recruiting
NCT03411031 Phase II Elotuzumab + Lenalidomide Dexamethasone Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide Recruiting
NCT03412565 Phase II Bortezomib + Daratumumab + Dexamethasone + Melphalan + Prednisone Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens Recruiting
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Recruiting
NCT03481556 Phase Ib/II Bortezomib + Dexamethasone + Melflufen Daratumumab + Dexamethasone + Melflufen Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With RRMM (ANCHOR) Recruiting
NCT03492138 Phase Ib/II Dexamethasone + Ixazomib + ONC201 Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Recruiting
NCT03502577 Phase I Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine + LY3039478 BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma Recruiting
NCT03506802 Phase I Filgrastim + Plerixafor Lenalidomide Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC Melphalan TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma Withdrawn
NCT03525678 Phase II GSK2857916 A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody Active, not recruiting
NCT03530683 Phase I TTI-622 A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma Recruiting
NCT03539744 Phase III Dexamethasone + Pomalidomide Dexamethasone + Venetoclax A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (CANOVA) Recruiting
NCT03544281 Phase II Bortezomib + Dexamethasone + GSK2857916 Dexamethasone + GSK2857916 + Lenalidomide To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) Recruiting
NCT03548207 Phase Ib/II JNJ-68284528 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma Recruiting
NCT03567616 Phase II Dexamethasone + Pomalidomide + Venetoclax A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Suspended
NCT03582033 Phase I SEA-BCMA A Safety Study of SEA-BCMA in Patients With Multiple Myeloma Recruiting
NCT03601078 Phase II bb2121 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2) Recruiting
NCT03602612 Phase I Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma Recruiting
NCT03605719 Phase I Carfilzomib + Dexamethasone + Nivolumab + Reolysin Carfilzomib + Dexamethasone + Nivolumab Dexamethasone, Carfilzomib, & Nivolumab With Reovirus for Relapsed/Refractory Multiple Myeloma Recruiting
NCT03607643 Phase Ib/II Temozolomide Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Not yet recruiting
NCT03634800 Phase II Nivolumab Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) (RISE-M) Recruiting
NCT03651128 Phase III Bortezomib + Daratumumab + Dexamethasone bb2121 Dexamethasone + Ixazomib + Lenalidomide Daratumumab + Dexamethasone + Pomalidomide Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) Recruiting
NCT03652064 Phase III Bortezomib + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Recruiting
NCT03657420 Phase I Dexamethasone + Nab-Rapamycin + Pomalidomide Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma Not yet recruiting
NCT03687125 Phase Ib/II Tinostamustine Tinostamustine Conditioning and Autologous Stem Cell (TITANIUM1) Terminated
NCT03701321 Phase Ib/II Bortezomib + Daratumumab + Dexamethasone Bortezomib + Daratumumab + Dexamethasone + Venetoclax Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma Suspended
NCT03713294 Phase II Dexamethasone + Elotuzumab + Pomalidomide Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma Recruiting
NCT03729804 Phase III Bortezomib + Dexamethasone + Lenalidomide Carfilzomib + Dexamethasone + Lenalidomide Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA)) Recruiting
NCT03732703 Phase Ib/II Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG) Recruiting
NCT03741127 Phase I Rimiducid Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 Enrolling by invitation
NCT03763162 Phase II Bortezomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Ixazomib Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Recruiting
NCT03773107 Phase Ib/II Carfilzomib + Dexamethasone + Ruxolitinib LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma Recruiting
NCT03782064 Phase II DC/myeloma fusion vaccine + Nivolumab Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma Recruiting
NCT03785184 Phase II Dexamethasone + Lenalidomide + Venetoclax A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy Suspended
NCT03829020 Phase I Metformin + Nelfinavir Bortezomib + Metformin + Nelfinavir Metformin and Nelfinavir in Treating Patients With Relapsed and/or Refractory Multiple Myeloma Recruiting
NCT03837509 Phase Ib/II Daratumumab + INCB001158 Daratumumab INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma Not yet recruiting
NCT03848845 Phase II GSK2857916 + Pembrolizumab Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 4) Recruiting
NCT03910439 Phase II Avelumab Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma Recruiting
NCT03942224 Phase II Daratumumab + Dexamethasone + Ixazomib Bortezomib + Daratumumab + Dexamethasone Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE) Recruiting
NCT03958656 Phase I Anti-SLAMF7 CAR T cells + Cyclophosphamide + Fludarabine Rimiducid T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma Recruiting